DKK 411.6
(6.85%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | -403.98 Million DKK | 0.0% |
2022 | - DKK | -100.0% |
2021 | 1.00 DKK | 0.0% |
2020 | 1.00 DKK | 0.0% |
2019 | - DKK | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 5.62 Million DKK | 101.39% |
2024 Q2 | 5.62 Million DKK | -100.0% |
2023 FY | -403.98 Million DKK | 0.0% |
2023 Q3 | -403.98 Million DKK | 3.95% |
2023 Q2 | -420.61 Million DKK | 0.0% |
2023 Q4 | -403.98 Million DKK | 0.0% |
2023 Q1 | -420.61 Million DKK | 0.0% |
2022 Q4 | - DKK | 0.0% |
2022 FY | - DKK | -100.0% |
2022 Q3 | - DKK | 0.0% |
2022 Q1 | - DKK | 0.0% |
2021 FY | 1.00 DKK | 0.0% |
2020 FY | 1.00 DKK | 0.0% |
2019 FY | - DKK | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
ALK-Abelló A/S | 1.42 Billion DKK | 128.39% |
Bavarian Nordic A/S | 1.64 Billion DKK | 124.577% |
Genmab A/S | 57 Million DKK | 808.753% |
Novo Nordisk A/S | 31.81 Billion DKK | 101.27% |
Orphazyme A/S | -1099.00 DKK | -36759590.628% |
Pharma Equity Group A/S | 1000.00 DKK | 40399000.0% |
Zealand Pharma A/S | 7.93 Million DKK | 5191.229% |